Navigation Links
New lung cancer drug shows dramatic results for shrinking tumors
Date:6/22/2010

Media Contact: Karen Shea 61

Patients with a specific kind of lung cancer may benefit from a Phase III clinical trial offered by the Moores UCSD Cancer Center. The new drug, crizotinib, under development by Pfizer, showed dramatic results in reducing lung cancer tumors in some patients during Phase I and II clinical trials.

"The results of the first two trials have been very encouraging," said Lyudmila Bazhenova, MD, assistant clinical professor at UC San Diego School of Medicine and a member of the Moores UCSD Cancer Center. "The Phase III clinical trials will be critical in determining if this drug goes to market."

According to a preliminary study presented at the 2010 meeting of the American Society of Clinical Oncology, Phase I/II clinical trials demonstrated that 57% of patients had their tumors reduced and at eight weeks of the treatment, 87% showed disease stabilization.

In some patients with non-small cell lung cancer (NSCLC), the anaplastic lymphoma kinase (ALK) gene may move and fuse with another gene, EML4. The resultant fusion produces an enzyme that promotes lung cancer cell growth. This fusion happens in approximately four percent of NSCLC patients. The chances of a patient having the fusion gene increases if they have the adenocarcinoma subtype of lung cancer, or are non-smokers or former light smokers, among other characteristics. Those patients have an approximate 20% chance of having this mutation. Crizotinib inhibits the enzyme, allowing the cancer cells to die off.

The Phase III clinical trial will compare crizotinib with standard-of-care chemotherapy in the treatment of ALK-positive recurrent NSCLC. Through a randomized selection process, patients will either be treated with chemotherapy or crizotinib. If the patients who are given the chemotherapy do not respond to treatment, they will be given crizotinib at the end of the trial.


'/>"/>

Contact: Karen Shea
kshea@ucsd.edu
619-543-6163
University of California - San Diego
Source:Eurekalert

Page: 1

Related medicine news :

1. Scripps Announces Plans for Region's First Proton Therapy Center; $185 Million Facility to Offer Advanced Care to Cancer Patients
2. Chlordecone exposure and risk of prostate cancer
3. Kids Into Safe Skin (K.I.S.S) Officially Launches Today with a Mission to Create Awareness About Skin Cancer Detection and Prevention
4. Cancer and Multiple Sclerosis Survivor Martin Smith's 3,000-mile Bicycle Ride Benefits Cancer Research
5. Cancers of sweat glands, other skin-related structures may be increasing in United States
6. New drugs to relieve cancer pain
7. Hematology-Oncology Associates of Northern New Jersey (HOANNJ) Joins Effort to Improve Cancer Care with Via Oncology™ Pathways
8. Coffee Might Guard Against Head, Neck Cancers
9. Surveillance may be suitable treatment option for patients with low-risk prostate cancer
10. Watchful Waiting Often Best Strategy for Slow-Moving Prostate Cancer
11. Second Ohio State cancer drug begins clinical trials testing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... Stamford, CT (PRWEB) July 11, 2014 ... – the nation’s only non-profit dedicated exclusively to ... announced that Joshua Corday has joined the organization ... veteran fundraising professional with deep experience securing gifts ... he served as Annual Giving Director for NewYork ...
(Date:7/11/2014)... Global enterprises today are shifting towards the changing ... Managed services offer these global enterprises a strategic method ... into rising operational costs to companies. The aim to ... the global market driver for expanding the managed services ... market is estimated to grow from $142.75 billion in ...
(Date:7/11/2014)... 11, 2014 Presently, disposable medical suppliers ... equipment and supplies segment. During the past two decades, ... growth (on an average 12.5% per year), primarily owing ... Currently, the US is the largest market for disposable ... of 40%. The second position is held by Europe ...
(Date:7/11/2014)... PROVIDENCE, R.I. -- Researchers from The Miriam ... under age 65 have significantly higher rates of ... with mobility impairments were less likely to attempt ... quit-smoking treatments may not be sufficient for this ... online in advance of print in the ...
(Date:7/11/2014)... largest study of its kind has found that ... advantages over their conventional counterparts, including more antioxidants ... study looked at an unprecedented 343 peer-reviewed publications ... and conventional plant-based foods, including fruits, vegetables, and ... to quantify differences between organic and non-organic foods. ...
Breaking Medicine News(10 mins):Health News:Alliance for Cancer Gene Therapy (ACGT) Welcomes Joshua Corday as Senior Development Officer 2Health News:Alliance for Cancer Gene Therapy (ACGT) Welcomes Joshua Corday as Senior Development Officer 3Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 4Health News:Global Disposable Medical Supplies Market to See Robust Growth Through Next Decade, According to New TriMark Report Available at MarketPublishers.com 2Health News:Global Disposable Medical Supplies Market to See Robust Growth Through Next Decade, According to New TriMark Report Available at MarketPublishers.com 3Health News:Miriam Hospital study examines smoking prevalence 2Health News:Major study documents nutritional and food safety benefits of organic farming 2Health News:Major study documents nutritional and food safety benefits of organic farming 3
... trips to their GP under a new scheme that has ... The electronic transfer of repeat prescriptions between general practices and ... a bid to streamline the system and make it faster ... down on prescription errors. , And now the scheme is ...
... be much tougher than is typically done, study finds , ... small (1 centimeter or less), certain kinds of breast cancer ... researchers say. , A team at the Mayo Clinic in ... (HER2+) and triple negative (HER2- and ER/PR-) tumors that have ...
... (Oakland, Calif.) The Agency for Healthcare Research and ... Health Research for a study that uses electronic medical ... 175,000 adults to find ways to improve the quality ... which will begin to yield findings next summer, will ...
... Dec. 17 Incisionless surgery is the,most significant ... being,rapidly adopted by a wide variety of academic ... StomaphyX(TM) and EsophyX(TM) procedures already,performed globally. Despite the ... clearance this year, over 50 U.S. centers,have already ...
... babies are born with severe heart defects that must be operated ... odds for these infants are much better now than they were ... be a way to give them an even better chance at ... at handling such cases. , In the first national study of ...
... Find items or activities that stretch youngsters, creativity and ... 16 (HealthDay News) -- When you,re Christmas shopping for ... toys that promote healthy childhood development and reinforce personal ... allow for creativity, imagination, manipulation, and change. If a ...
Cached Medicine News:Health News:Prescription for an electronic revolution? 2Health News:Prescription for an electronic revolution? 3Health News:Even Tiny Breast Tumors May Need Aggressive Treatment 2Health News:Agency for Healthcare Research and Quality funds KP study of electronic records for heart disease 2Health News:EndoGastric Solutions Opens Three Training Centers to Keep Up with Demand from Surgeons Wanting to Learn StomaphyX(TM) Procedures 2Health News:EndoGastric Solutions Opens Three Training Centers to Keep Up with Demand from Surgeons Wanting to Learn StomaphyX(TM) Procedures 3Health News:EndoGastric Solutions Opens Three Training Centers to Keep Up with Demand from Surgeons Wanting to Learn StomaphyX(TM) Procedures 4Health News:For babies with heart defects, death risk is far lower at most experienced hospitals 2Health News:For babies with heart defects, death risk is far lower at most experienced hospitals 3Health News:For babies with heart defects, death risk is far lower at most experienced hospitals 4Health News:Picking the Right Toys Isn't Child's Play 2
(Date:7/11/2014)... July 11, 2014 On ... down 0.52%, the Dow Jones Industrial Average finished the day ... 1,964.68, down 0.41%. The losses were broad based as eight ... S&P 500 Health Care Sector Index ended the day at ... the last one month. Investor-Edge has initiated coverage on the ...
(Date:7/11/2014)... Research and Markets ( http://www.researchandmarkets.com/research/tjlw9k/immunoprotein ) ... Diagnostic Testing Market - Forecasts to 2019: Expected ... and is expected to be valued at USD ... http://photos.prnewswire.com/prnh/20130307/600769 ... segmented according to immunoprotein types which include immunoglobulins, ...
(Date:7/11/2014)... Show organisers report ... Expo 2014 were a brand new audience ... London , plus a 10% increase ...      (Logo: http://photos.prnewswire.com/prnh/20130723/629764-a) ...      (Photo: http://photos.prnewswire.com/prnh/20140711/696892-b ) ...
Breaking Medicine Technology:Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 4
... 6, 2011 The Female Health Company (NASDAQ-CM: FHCO) ... Industria e Comercio (Semina), was successful in a public ... with up to 20 million FC2 Female Condoms.  The ... quantity purchased will be determined at the Ministry of ...
... InspireMD, Inc. (OTC BB: NSPR) ("Inspire" or the ... system, today announced that Mr. Ofir Paz, InspireMD,s co-founder ... financial officer, will participate in the Benchmark Company, LLC ... The Pfister Hotel, 424 East Wisconsin Ave., Milwaukee, Wis. ...
Cached Medicine Technology:The Female Health Company's Brazilian Distributor, Semina, Awarded Contract For Up To 20 Million FC2 Female Condoms 2The Female Health Company's Brazilian Distributor, Semina, Awarded Contract For Up To 20 Million FC2 Female Condoms 3InspireMD to Participate in Benchmark Company, LLC 2011 One-On-One Investor Conference 2InspireMD to Participate in Benchmark Company, LLC 2011 One-On-One Investor Conference 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: